SEC Form 4 · accession 0000899243-18-002279
ARMO BioSciences, Inc. · ARMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Xiangmin Cui
Director
Period of report
Jan 30, 2018
Accepted (ET)
Jan 30, 2018 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001693664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Jan 30, 2018 | C | 1,214,700 | — | A | 1,214,700 | I | By Decheng Capital China Life Sciences USD Fund II, L.P. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C-1 Convertible Preferred StockF3,F4,F2 | — | Jan 30, 2018 | C | 1,214,700 | D | — | — | Common Stock | 1,214,700 | 0 | I |
Explanation of responses
- F1The total represents shares received upon conversion of shares of Series C-1 Convertible Preferred Stock.
- F2Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date.
- F3These Shares are held of record held by Decheng Capital China Life Sciences USD Fund II, L.P. (Decheng Capital). Decheng Capital Management II (Cayman), LLC (Decheng Management) serves as the general partner of Decheng Capital and possesses the power to direct the voting and disposition of the shares owned by Decheng Capital. The Reporting Person is the sole director and sole voting shareholder of Decheng Management and has sole voting and dispositive power over the shares held by Decheng Capital. The Reporting Person disclaims beneficial ownership of the shares held by Decheng Capital, except to the extent of his pecuniary interest.
- F4Each of Decheng Capital and the Reporting Person disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.